
NAD+
NAD+ precursor. Reviewed across preclinical mitochondrial-bioenergetic and metabolic models.[1]
PayPal or cash on collection · UK 18+ verification at checkout · For laboratory research use only
Selected research · NAD+
- [1]Mechanistic review of NAD+ precursors NMN and NR across preclinical models and emerging clinical trials.Yoshino J, Baur JA, Imai SI. (2018). NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metabolism.PMID 29249689 →
All references describe published research on the compound. They do not constitute clinical guidance or imply therapeutic benefit to any individual purchaser. For laboratory research use only.
Frequently bought together
Full catalogue →MOTS-C
Mitochondrial-derived peptide. Studied in preclinical research on AMPK activation and metabolic-regulation pathways.
From £75.00
KPV
Tripeptide derived from alpha-MSH. Studied in preclinical anti-inflammatory and gastrointestinal research. Commonly referenced in research-compound groupings.
From £30.00
SS-31 (Elamipretide)
Mitochondria-targeted peptide. Studied in preclinical research on inner-mitochondrial-membrane stabilisation and cellular-energy endpoints.
From £40.00
Tesamorelin
GHRH analogue. Studied in clinical research on growth-hormone secretion and visceral-adiposity endpoints.
From £55.00
Often stacked with NAD+
Full catalogue →Epitalon
Synthetic tetrapeptide. Studied in preclinical research on telomerase activation and pineal-gland function. Referenced in cellular-senescence research.
SS-31 (Elamipretide)
Mitochondria-targeted peptide. Studied in preclinical research on inner-mitochondrial-membrane stabilisation and cellular-energy endpoints.
MOTS-C
Mitochondrial-derived peptide. Studied in preclinical research on AMPK activation and metabolic-regulation pathways.
